Galecto, Inc. Common Stock (GLTO) Stock Price
GLTOStock
$30.31+807.49%52W
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta1.41
GLTO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.87%
Price vs S&P 500 (4W)-0.03%
VGM Score75.25
GLTO Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.29
4.29
4.38
4.30
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
GLTOGalecto, Inc. Common Stock | — | — | B | $30.31 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Galecto, Inc. Common Stock
Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for cancer and liver diseases. Its pipeline includes three candidates: GB0139 for idiopathic pulmonary fibrosis, GB1211 for NASH-related fibrosis, and GB2064 for myelofibrosis.